Maze Therapeutics Earnings
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Maze Therapeutics earnings summary
In its most recent report on Nov 9, 2026 (Sep/2026), MAZE posted EPS of $-0.79 versus the $-0.78 consensus estimate, a negative surprise of 1.3%. Maze Therapeutics beat the consensus EPS estimate in 1 of the last 2 quarters, with a median surprise of +7.1%. Across the last 9 reports, MAZE shares moved an average of 6.9% (in either direction) in the first trading session after results, rising 5 times and falling 4 times.
Summary generated from market data by MetaCap's automated system. Methodology
MAZE earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Nov 9, 2026 | $-0.78 | $-0.79 | -1.3% | -8.6% |
| Nov 5, 2026 | $-0.78 | $-0.66 | +15.4% | +0.4% |
| Aug 11, 2026 | — | $-0.76 | — | +8.3% |
| May 12, 2026 | — | $-0.45 | — | +0.9% |
| Mar 25, 2026 | — | $-0.47 | — | -5.5% |
| Nov 6, 2025 | — | $-0.66 | — | +13.7% |
| Aug 12, 2025 | — | $-0.77 | — | -0.1% |
| May 14, 2025 | — | $-1.15 | — | +11.1% |
| Mar 31, 2025 | — | $22.19 | — | -13.7% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.